| Diagnosis classification . | Patients, n (%) . | Female, n (%) . | Visceral involvement, n (%) . | Active SLE, n (%) . | Predominant cutaneous lesions (%) . | Predominant locations (%) . | Relapse, n (%) . | Delay before relapse, median (IQR), months . |
|---|---|---|---|---|---|---|---|---|
| Retained diagnosis | ||||||||
| Urticarial vasculitisa | 14 (36) | 14 (100) | 1 (7) | 5/13 (38) | Urticarial lesions (100), palpable purpura (29) | Legs (86), trunk/abdomen (71), arms (57), palms/digits (14) | 6/13 (46) | 36 (16–49) |
| Cryoglobulinaemic vasculitis | 13 (33) | 12 (92) | 7 (54) | 3 (23) | Palpable purpura (77), ulcero-necrotic (31), urticarial lesions (23) | Legs (85), arms (15), palms/digits (15) | 8 (62) | 24 (10–63) |
| SLE-related vasculitis | 2 (5) | 2 (100) | 0 (0) | 2 (100) | Palpable purpura (100)/erythematous macules or papules (50) | Legs (100) | 1 (50) | 11 |
| Drug-induced vasculitisb | 1 (3) | 1 (100) | 0 (0) | 0 (0) | Urticarial lesions | Trunk and abdomen | 0 (0) | — |
| Uncertain diagnosis | ||||||||
| SLE or Sjögren’s syndrome-related vasculitis | 5 (13) | 3 (60) | 3 (60) | 2 (40) | Palpable purpura (80), erythematous macules and papules (20) | Legs (100), palms/digits (20) | 0 (0) | — |
| SLE with concomitant infectionc | 2 (5) | 2 (100) | 0 (0) | 1 (50) | Ulcerations (100), necrosis (50), erythematous macules and papules (50) | Palms (100), arms (50), legs (50) | 0 (0) | — |
| SLE with concomitant infection, neoplasia and cryoglobulinaemiad | 1 (3) | 0 (0) | 0 (0) | 1 (100) | Erythematous macules and papules with ulcerations | Legs | 0 (0) | — |
| SLE or cryoglobulinaemic-related vasculitis | 1 (3) | 1 (100) | 0 (0) | 1 (100) | Palpable purpura and livedo reticularis | Palms and digits | 0 (0) | — |
| Diagnosis classification . | Patients, n (%) . | Female, n (%) . | Visceral involvement, n (%) . | Active SLE, n (%) . | Predominant cutaneous lesions (%) . | Predominant locations (%) . | Relapse, n (%) . | Delay before relapse, median (IQR), months . |
|---|---|---|---|---|---|---|---|---|
| Retained diagnosis | ||||||||
| Urticarial vasculitisa | 14 (36) | 14 (100) | 1 (7) | 5/13 (38) | Urticarial lesions (100), palpable purpura (29) | Legs (86), trunk/abdomen (71), arms (57), palms/digits (14) | 6/13 (46) | 36 (16–49) |
| Cryoglobulinaemic vasculitis | 13 (33) | 12 (92) | 7 (54) | 3 (23) | Palpable purpura (77), ulcero-necrotic (31), urticarial lesions (23) | Legs (85), arms (15), palms/digits (15) | 8 (62) | 24 (10–63) |
| SLE-related vasculitis | 2 (5) | 2 (100) | 0 (0) | 2 (100) | Palpable purpura (100)/erythematous macules or papules (50) | Legs (100) | 1 (50) | 11 |
| Drug-induced vasculitisb | 1 (3) | 1 (100) | 0 (0) | 0 (0) | Urticarial lesions | Trunk and abdomen | 0 (0) | — |
| Uncertain diagnosis | ||||||||
| SLE or Sjögren’s syndrome-related vasculitis | 5 (13) | 3 (60) | 3 (60) | 2 (40) | Palpable purpura (80), erythematous macules and papules (20) | Legs (100), palms/digits (20) | 0 (0) | — |
| SLE with concomitant infectionc | 2 (5) | 2 (100) | 0 (0) | 1 (50) | Ulcerations (100), necrosis (50), erythematous macules and papules (50) | Palms (100), arms (50), legs (50) | 0 (0) | — |
| SLE with concomitant infection, neoplasia and cryoglobulinaemiad | 1 (3) | 0 (0) | 0 (0) | 1 (100) | Erythematous macules and papules with ulcerations | Legs | 0 (0) | — |
| SLE or cryoglobulinaemic-related vasculitis | 1 (3) | 1 (100) | 0 (0) | 1 (100) | Palpable purpura and livedo reticularis | Palms and digits | 0 (0) | — |
Including n = 10 hypocomplementaemic urticarial vasculitis, n = 1 normocomplementaemic urticarial vasculitis and n = 3 non-classifiable (insufficient data).
Related to rituximab injection (serum sickness syndrome).
One pneumonia with sepsis (no bacterial identification) and one primo-cytomegalovirus infection.
SLE flare with type III cryoglobulinaemia associated with Klebsiella pneumonia infection revealing lung carcinoma.
CV: cutaneous vasculitis; IQR: interquartile range.
| Diagnosis classification . | Patients, n (%) . | Female, n (%) . | Visceral involvement, n (%) . | Active SLE, n (%) . | Predominant cutaneous lesions (%) . | Predominant locations (%) . | Relapse, n (%) . | Delay before relapse, median (IQR), months . |
|---|---|---|---|---|---|---|---|---|
| Retained diagnosis | ||||||||
| Urticarial vasculitisa | 14 (36) | 14 (100) | 1 (7) | 5/13 (38) | Urticarial lesions (100), palpable purpura (29) | Legs (86), trunk/abdomen (71), arms (57), palms/digits (14) | 6/13 (46) | 36 (16–49) |
| Cryoglobulinaemic vasculitis | 13 (33) | 12 (92) | 7 (54) | 3 (23) | Palpable purpura (77), ulcero-necrotic (31), urticarial lesions (23) | Legs (85), arms (15), palms/digits (15) | 8 (62) | 24 (10–63) |
| SLE-related vasculitis | 2 (5) | 2 (100) | 0 (0) | 2 (100) | Palpable purpura (100)/erythematous macules or papules (50) | Legs (100) | 1 (50) | 11 |
| Drug-induced vasculitisb | 1 (3) | 1 (100) | 0 (0) | 0 (0) | Urticarial lesions | Trunk and abdomen | 0 (0) | — |
| Uncertain diagnosis | ||||||||
| SLE or Sjögren’s syndrome-related vasculitis | 5 (13) | 3 (60) | 3 (60) | 2 (40) | Palpable purpura (80), erythematous macules and papules (20) | Legs (100), palms/digits (20) | 0 (0) | — |
| SLE with concomitant infectionc | 2 (5) | 2 (100) | 0 (0) | 1 (50) | Ulcerations (100), necrosis (50), erythematous macules and papules (50) | Palms (100), arms (50), legs (50) | 0 (0) | — |
| SLE with concomitant infection, neoplasia and cryoglobulinaemiad | 1 (3) | 0 (0) | 0 (0) | 1 (100) | Erythematous macules and papules with ulcerations | Legs | 0 (0) | — |
| SLE or cryoglobulinaemic-related vasculitis | 1 (3) | 1 (100) | 0 (0) | 1 (100) | Palpable purpura and livedo reticularis | Palms and digits | 0 (0) | — |
| Diagnosis classification . | Patients, n (%) . | Female, n (%) . | Visceral involvement, n (%) . | Active SLE, n (%) . | Predominant cutaneous lesions (%) . | Predominant locations (%) . | Relapse, n (%) . | Delay before relapse, median (IQR), months . |
|---|---|---|---|---|---|---|---|---|
| Retained diagnosis | ||||||||
| Urticarial vasculitisa | 14 (36) | 14 (100) | 1 (7) | 5/13 (38) | Urticarial lesions (100), palpable purpura (29) | Legs (86), trunk/abdomen (71), arms (57), palms/digits (14) | 6/13 (46) | 36 (16–49) |
| Cryoglobulinaemic vasculitis | 13 (33) | 12 (92) | 7 (54) | 3 (23) | Palpable purpura (77), ulcero-necrotic (31), urticarial lesions (23) | Legs (85), arms (15), palms/digits (15) | 8 (62) | 24 (10–63) |
| SLE-related vasculitis | 2 (5) | 2 (100) | 0 (0) | 2 (100) | Palpable purpura (100)/erythematous macules or papules (50) | Legs (100) | 1 (50) | 11 |
| Drug-induced vasculitisb | 1 (3) | 1 (100) | 0 (0) | 0 (0) | Urticarial lesions | Trunk and abdomen | 0 (0) | — |
| Uncertain diagnosis | ||||||||
| SLE or Sjögren’s syndrome-related vasculitis | 5 (13) | 3 (60) | 3 (60) | 2 (40) | Palpable purpura (80), erythematous macules and papules (20) | Legs (100), palms/digits (20) | 0 (0) | — |
| SLE with concomitant infectionc | 2 (5) | 2 (100) | 0 (0) | 1 (50) | Ulcerations (100), necrosis (50), erythematous macules and papules (50) | Palms (100), arms (50), legs (50) | 0 (0) | — |
| SLE with concomitant infection, neoplasia and cryoglobulinaemiad | 1 (3) | 0 (0) | 0 (0) | 1 (100) | Erythematous macules and papules with ulcerations | Legs | 0 (0) | — |
| SLE or cryoglobulinaemic-related vasculitis | 1 (3) | 1 (100) | 0 (0) | 1 (100) | Palpable purpura and livedo reticularis | Palms and digits | 0 (0) | — |
Including n = 10 hypocomplementaemic urticarial vasculitis, n = 1 normocomplementaemic urticarial vasculitis and n = 3 non-classifiable (insufficient data).
Related to rituximab injection (serum sickness syndrome).
One pneumonia with sepsis (no bacterial identification) and one primo-cytomegalovirus infection.
SLE flare with type III cryoglobulinaemia associated with Klebsiella pneumonia infection revealing lung carcinoma.
CV: cutaneous vasculitis; IQR: interquartile range.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
